Peng Deng

Twenty-five sheep, experimentally (n = 15) or naturally (n = 6) infected with ovine progressive pneumonia virus and noninfected controls (n = 4), were evaluated for histological and ultrastructural lesions of mastitis. Histologically, nine of 15 experimentally infected sheep and all six naturally infected sheep had lympho-plasmacytic mastitis. Severity of the lesion increased with length of time after infection. Periductal lymphatic nodules were seen in five sheep experimentally infected for 2.8 years or longer and in five naturally infected sheep that were 3.7 years old or older. Ultrastructurally, responses to ovine progressive pneumonia virus were diffuse lympho-plasmacytic infiltrates in glandular interstitium, lymphocytic and occasional plasmacytic infiltrates in ductal walls and lumens, lymphoblasts surrounded by small lymphocytes in glandular interstitium, and degeneration of epithelium releasing cells and cellular debris into the lumen. Based on the prevalence of lesions, the mammary tissue was more susceptible to ovine progressive pneumonia virus than other target organs: lung, brain, and synovium. Lesions did not differ between breeds of sheep. Ovine progressive pneumonia virus was not seen in the mammary tissue but was isolated from 15 of 17 mammary glands.

BACKGROUND: A novel intranasal influenza vaccine named Ganwu® was approved in 2020 for children aged 3-17 years in China. This study aimed to conduct a phase IV clinical trial to assess the effectiveness and safety of this vaccine. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled phase IV clinical trial to evaluate the effectiveness and safety of Ganwu® vaccine in children aged 3-17 years in China during 2023 to 2024 influenza season. The influenza-like illnesses (ILIs) were monitored in the vaccine and placebo groups during a follow-up period of seven months, and nasopharyngeal specimens from ILI cases were collected for laboratory confirmation of influenza virus. Primary endpoints included vaccine effectiveness against laboratory-confirmed influenza and ILI, with comprehensive safety monitoring throughout the study period. RESULTS: The trial enrolled 6000 participants, randomly allocated in a 1:1 ratio to receive either Ganwu® or placebo. The vaccine's effectiveness in preventing laboratory-confirmed influenza was 46.8 % (95 % confidence interval [CI] 25.8 %-61.9 %), with specific effectiveness rates of 30.4 % against A/H1N1, 55.1 % against A/H3N2, and 84.6 % against B/Victoria. Laboratory-confirmed influenza was significantly less frequent in the vaccine group (hazard ratio 0.53, 95 % CI 0.38-0.74). Effectiveness of Ganwu® vaccine against ILI was 15.2 % (95 % CI -2.3 %-29.7 %). Safety assessments demonstrated comparable incidence of solicited adverse events (AE) between groups, with the incidence of grade three or higher AEs below 1 %. Among 12 reported serious AEs, none were attributed to vaccination. CONCLUSIONS: Ganwu® vaccine provided moderate protection against laboratory-confirmed influenza among children with good safety profile.

We aimed to investigate the clinical effectiveness of integrating 3D-printing technology with neuroendoscopy for treating hypertensive intracerebral hemorrhage (HICH). Between November 2020 and November 2023, a total of 105 HICH cases were selected and categorized into the conventional surgery group and the neuroendoscopic surgery. General data, Glasgow Coma Scale (GCS), National institutes of health neurological impairment score (NIHSS), preoperative hematoma volume, intracerebral parenchymal and intraventricular hematoma (IVH) clearance rates, Modified Graeb Scale (mGS), postoperative rebleeding rate, intracranial infection, and Modified Rankin Scale (mRS) were collected to assess the therapeutic effectiveness. There were no significant statistical differences in gender, age, preoperative GCS scores, NIHSS or hematoma volume between the neuroendoscopic surgery and conventional surgery group. The postoperative results indicated that the clearance rate of intracerebral parenchymal and IVH in neuroendoscopic surgery group was notably higher than the conventional surgery group. The neuroendoscopic surgery group achieved superior outcomes in terms of bone flap area, operation time, extubation time, and average hospital stay compared to the conventional surgery group (P < 0.05). Following a 3-month follow-up, there was no significant difference in the mRS and NIHSS between the two groups. However, when the patients with IVH (mGS≥10) indicated better postoperative outcomes in the neuroendoscopic surgery group (P < 0.05). The integration of neuroendoscopic minimally invasive surgery with 3D-printing technology for treating HICH demonstrated high efficacy for removing intracerebral and IVH. This approach incurred less trauma compared to traditional craniectomy surgery, affording shortened surgical and hospitalization durations. Consequently, it appears to be a highly efficacious method for treating HICH, particularly in cases involving IVH.